Takzylo subcutaneous injection 300 mg syringe, manufactured by Takeda Pharmaceutical, contains lanadelumab (genetical recombination). This monoclonal antibody is used to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients aged 2 years and older by targeting plasma kallikrein. It is supplied as 300mg 2mL 1 tube with YJ code 4490407G1023.
Takzylo subcutaneous injection 300 mg syringe
Need more detailed information?
Contact TASAKI PHARMA for product sourcing, availability, or related support (English support available).